Quality of life and mood in patients with medically intractable epilepsy treated with targeted responsive neurostimulation

RNS System Pivotal Trial Investigators

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Purpose: The primary efficacy and safety measures from a trial of responsive neurostimulation for focal epilepsy were previously published. In this report, the findings from the same study are presented for quality of life, which was a supportive analysis, and for mood, which was assessed as a secondary safety endpoint. Methods: The study was a multicenter randomized controlled double-blinded trial of responsive neurostimulation in 191 patients with medically resistant focal epilepsy. During a 4-month postimplant blinded period, patients were randomized to receive responsive stimulation or sham stimulation, after which all patients received responsive neurostimulation in open label to complete 2. years. Quality of life (QOL) and mood surveys were administered during the baseline period, at the end of the blinded period, and at year 1 and year 2 of the open label period. Results: The treatment and sham groups did not differ at baseline. Compared with baseline, QOL improved in both groups at the end of the blinded period and also at 1. year and 2. years, when all patients were treated. At 2. years, 44% of patients reported meaningful improvements in QOL, and 16% reported declines. There were no overall adverse changes in mood or in suicidality across the study. Findings were not related to changes in seizures and antiepileptic drugs, and patients with mesial temporal seizure onsets and those with neocortical seizure onsets both experienced improvements in QOL. Conclusions: Treatment with targeted responsive neurostimulation does not adversely affect QOL or mood and may be associated with improvements in QOL in patients, including those with seizures of either mesial temporal origin or neocortical origin.

Original languageEnglish (US)
Pages (from-to)242-247
Number of pages6
JournalEpilepsy and Behavior
Volume45
DOIs
StatePublished - Apr 1 2015

Fingerprint

Quality of Life
Seizures
Partial Epilepsy
Safety
Drug Resistant Epilepsy
Anticonvulsants
Placebos
Therapeutics

Keywords

  • Brain stimulation
  • Depression
  • Epilepsy
  • Intractable seizures
  • Quality of life
  • Responsive stimulation

ASJC Scopus subject areas

  • Clinical Neurology
  • Behavioral Neuroscience
  • Neurology

Cite this

Quality of life and mood in patients with medically intractable epilepsy treated with targeted responsive neurostimulation. / RNS System Pivotal Trial Investigators.

In: Epilepsy and Behavior, Vol. 45, 01.04.2015, p. 242-247.

Research output: Contribution to journalArticle

@article{b1fa95217e4b44d594b578f751b1ff40,
title = "Quality of life and mood in patients with medically intractable epilepsy treated with targeted responsive neurostimulation",
abstract = "Purpose: The primary efficacy and safety measures from a trial of responsive neurostimulation for focal epilepsy were previously published. In this report, the findings from the same study are presented for quality of life, which was a supportive analysis, and for mood, which was assessed as a secondary safety endpoint. Methods: The study was a multicenter randomized controlled double-blinded trial of responsive neurostimulation in 191 patients with medically resistant focal epilepsy. During a 4-month postimplant blinded period, patients were randomized to receive responsive stimulation or sham stimulation, after which all patients received responsive neurostimulation in open label to complete 2. years. Quality of life (QOL) and mood surveys were administered during the baseline period, at the end of the blinded period, and at year 1 and year 2 of the open label period. Results: The treatment and sham groups did not differ at baseline. Compared with baseline, QOL improved in both groups at the end of the blinded period and also at 1. year and 2. years, when all patients were treated. At 2. years, 44{\%} of patients reported meaningful improvements in QOL, and 16{\%} reported declines. There were no overall adverse changes in mood or in suicidality across the study. Findings were not related to changes in seizures and antiepileptic drugs, and patients with mesial temporal seizure onsets and those with neocortical seizure onsets both experienced improvements in QOL. Conclusions: Treatment with targeted responsive neurostimulation does not adversely affect QOL or mood and may be associated with improvements in QOL in patients, including those with seizures of either mesial temporal origin or neocortical origin.",
keywords = "Brain stimulation, Depression, Epilepsy, Intractable seizures, Quality of life, Responsive stimulation",
author = "{RNS System Pivotal Trial Investigators} and Meador, {Kimford J.} and Ritu Kapur and Loring, {David W.} and Kanner, {Andres M} and Morrell, {Martha J.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.yebeh.2015.01.012",
language = "English (US)",
volume = "45",
pages = "242--247",
journal = "Epilepsy and Behavior",
issn = "1525-5050",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Quality of life and mood in patients with medically intractable epilepsy treated with targeted responsive neurostimulation

AU - RNS System Pivotal Trial Investigators

AU - Meador, Kimford J.

AU - Kapur, Ritu

AU - Loring, David W.

AU - Kanner, Andres M

AU - Morrell, Martha J.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Purpose: The primary efficacy and safety measures from a trial of responsive neurostimulation for focal epilepsy were previously published. In this report, the findings from the same study are presented for quality of life, which was a supportive analysis, and for mood, which was assessed as a secondary safety endpoint. Methods: The study was a multicenter randomized controlled double-blinded trial of responsive neurostimulation in 191 patients with medically resistant focal epilepsy. During a 4-month postimplant blinded period, patients were randomized to receive responsive stimulation or sham stimulation, after which all patients received responsive neurostimulation in open label to complete 2. years. Quality of life (QOL) and mood surveys were administered during the baseline period, at the end of the blinded period, and at year 1 and year 2 of the open label period. Results: The treatment and sham groups did not differ at baseline. Compared with baseline, QOL improved in both groups at the end of the blinded period and also at 1. year and 2. years, when all patients were treated. At 2. years, 44% of patients reported meaningful improvements in QOL, and 16% reported declines. There were no overall adverse changes in mood or in suicidality across the study. Findings were not related to changes in seizures and antiepileptic drugs, and patients with mesial temporal seizure onsets and those with neocortical seizure onsets both experienced improvements in QOL. Conclusions: Treatment with targeted responsive neurostimulation does not adversely affect QOL or mood and may be associated with improvements in QOL in patients, including those with seizures of either mesial temporal origin or neocortical origin.

AB - Purpose: The primary efficacy and safety measures from a trial of responsive neurostimulation for focal epilepsy were previously published. In this report, the findings from the same study are presented for quality of life, which was a supportive analysis, and for mood, which was assessed as a secondary safety endpoint. Methods: The study was a multicenter randomized controlled double-blinded trial of responsive neurostimulation in 191 patients with medically resistant focal epilepsy. During a 4-month postimplant blinded period, patients were randomized to receive responsive stimulation or sham stimulation, after which all patients received responsive neurostimulation in open label to complete 2. years. Quality of life (QOL) and mood surveys were administered during the baseline period, at the end of the blinded period, and at year 1 and year 2 of the open label period. Results: The treatment and sham groups did not differ at baseline. Compared with baseline, QOL improved in both groups at the end of the blinded period and also at 1. year and 2. years, when all patients were treated. At 2. years, 44% of patients reported meaningful improvements in QOL, and 16% reported declines. There were no overall adverse changes in mood or in suicidality across the study. Findings were not related to changes in seizures and antiepileptic drugs, and patients with mesial temporal seizure onsets and those with neocortical seizure onsets both experienced improvements in QOL. Conclusions: Treatment with targeted responsive neurostimulation does not adversely affect QOL or mood and may be associated with improvements in QOL in patients, including those with seizures of either mesial temporal origin or neocortical origin.

KW - Brain stimulation

KW - Depression

KW - Epilepsy

KW - Intractable seizures

KW - Quality of life

KW - Responsive stimulation

UR - http://www.scopus.com/inward/record.url?scp=84937760662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937760662&partnerID=8YFLogxK

U2 - 10.1016/j.yebeh.2015.01.012

DO - 10.1016/j.yebeh.2015.01.012

M3 - Article

VL - 45

SP - 242

EP - 247

JO - Epilepsy and Behavior

JF - Epilepsy and Behavior

SN - 1525-5050

ER -